PCOA yields 0.00% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 4
Combined, PCOA + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PCOA + JNJ for your $10,000?
Pendrell Corporation invests in, acquires, and develops businesses with technologies that are protected by intellectual property (IP) rights in the United States. It manages three IP licensing programs comprising memory and storage technologies, digital media, and digital cinema. The company's digital media program is supported by patents and patent applications to protect against unauthorized duplication and use of digital content during the transfer of the digital content. It grants digital media licenses to manufacturers, distributors, and providers of consumer products. The company's memory and storage technologies are used in electronic devices, including licensees of flash memory component suppliers, solid state disk manufacturers, and device vendors. Its digital cinema program is supported by DRM Patents and patent applications designed to protect against unauthorized creation, duplication and use of digital cinema content that is distributed to movie theaters worldwide. Its digital cinema licensees include distributors and exhibitors of digital content, such as motion picture producers, motion picture distributors, and equipment vendors. The company was formerly known as ICO Global Communications (Holdings) Limited and changed its name to Pendrell Corporation in July 2011. Pendrell Corporation was founded in 1995 and is headquartered in Kirkland, Washington.
Full PCOA Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.